A Retrospective, Real-world Multicenter Study of DOstarlimab in Patients With Recurrent or Advanced DNA Mismatch Repair Deficient/Microsatellite Instability-high (dMMR/MSI-H) Endometrial Cancer (DORA Study)
Latest Information Update: 27 Feb 2024
At a glance
- Drugs Dostarlimab (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DORA
Most Recent Events
- 22 Feb 2024 Planned End Date changed from 12 Sep 2023 to 12 Sep 2024.
- 22 Feb 2024 Planned primary completion date changed from 12 Aug 2023 to 12 Apr 2024.
- 24 Apr 2023 Planned End Date changed from 12 Mar 2023 to 12 Sep 2023.